# AzurRx BioPharma, Inc. (AZRX)

Source: https://www.quantisnow.com/company/AZRX
Generated: 2026-11-20T05:18:17.811Z

- Ticker: AZRX
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Major Pharmaceuticals
- IPO year: 2016
- Website: azurrx.com

## About

AzurRx BioPharma, Inc., a clinical stage biopharmaceutical company, focuses on the development of recombinant proteins for the treatment of gastrointestinal diseases. Its therapeutic products administer patients as oral non-systemic biologics. The company's lead therapeutic is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency. It is also developing two clinical programs using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor, including FW-420, for grade 1 Immune Checkpoint Inhibitor-associated colitis and diarrhea in oncology patients; and FW-1022, for COVID-19 gastrointestinal infections. AzurRx BioPharma, Inc. has a license agreement with First Wave Bio, Inc. The company was incorporated in 2014 and is based in Boca Raton, Florida.

## Latest AZRX news and filings

- 2021-09-28 21:16 UTC [SEC Form 8-K] [AzurRx BioPharma, Inc. filed SEC Form 8-K: Other Events](https://www.quantisnow.com/insight/azurrx-biopharma-inc-filed-sec-form-8-k-other-events-1819145)
- 2021-09-21 20:38 UTC [SEC Form 8-K] [AzurRx BioPharma, Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/azurrx-biopharma-inc-filed-sec-form-8-k-material-modification-to-1795318)
- 2021-09-21 16:47 UTC [AzurRx BioPharma to Change Corporate Name to First Wave BioPharma Today](https://www.quantisnow.com/insight/azurrx-biopharma-to-change-corporate-name-to-first-wave-biopharma-1794232)
- 2021-09-14 21:12 UTC [SEC Form 8-K] [AzurRx BioPharma, Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/azurrx-biopharma-inc-filed-sec-form-8-k-regulation-fd-disclosure-1771871)
- 2021-09-14 11:30 UTC [AzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave Bio and Creation of First Wave BioPharma](https://www.quantisnow.com/insight/azurrx-biopharma-ceo-issues-letter-to-shareholders-regarding-recent-acquisition-1767759)
- 2021-09-14 00:08 UTC [SEC Form 4] [SEC Form 4 filed by Coelho Mary Theresa](https://www.quantisnow.com/insight/sec-form-4-filed-by-coelho-mary-theresa-1766725)
- 2021-09-13 10:17 UTC [SEC Form 8-K] [AzurRx BioPharma, Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/azurrx-biopharma-inc-filed-sec-form-8-k-entry-into-a-1762878)
- 2021-09-13 10:00 UTC [Earnings Date] [AzurRx BioPharma Announces Acquisition of First Wave Bio and its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease Indications](https://www.quantisnow.com/insight/azurrx-biopharma-announces-acquisition-of-first-wave-bio-and-its-1762711)
- 2021-09-10 20:05 UTC [SEC Form 8-K] [AzurRx BioPharma, Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/azurrx-biopharma-inc-filed-sec-form-8-k-material-modification-to-1761244)
- 2021-09-10 16:45 UTC [AzurRx BioPharma Announces Reverse Stock Split](https://www.quantisnow.com/insight/azurrx-biopharma-announces-reverse-stock-split-1760689)
- 2021-09-10 12:30 UTC [AzurRx BioPharma Activates New Clinical Trial Sites in India for Phase 2 RESERVOIR Trial Evaluating Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections](https://www.quantisnow.com/insight/azurrx-biopharma-activates-new-clinical-trial-sites-in-india-for-1759505)
- 2021-09-09 12:30 UTC [AzurRx BioPharma Announces Positive Results from Independent Data Monitoring Committee Review of Safety Data from Part 1 of RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections](https://www.quantisnow.com/insight/azurrx-biopharma-announces-positive-results-from-independent-data-monitoring-committee-1754489)
- 2021-09-07 20:30 UTC [Conference Announcement] [AzurRx BioPharma to Present at the Virtual H.C. Wainwright 23rd Annual  Global Investment Conference](https://www.quantisnow.com/insight/azurrx-biopharma-to-present-at-the-virtual-hc-wainwright-23rd-1746897)
- 2021-08-18 12:53 UTC [SEC Form 8-K] [AzurRx BioPharma, Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/azurrx-biopharma-inc-filed-sec-form-8-k-regulation-fd-disclosure-1683126)
- 2021-08-18 11:05 UTC [Conference Announcement] [AzurRx BioPharma Announces Positive Topline Data For Phase 2 MS1819 Combination Therapy Trial in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency (EPI)](https://www.quantisnow.com/insight/azurrx-biopharma-announces-positive-topline-data-for-phase-2-ms1819-1682315)
- 2021-08-17 20:46 UTC [SEC Form 3] [SEC Form 3 filed by Coelho Mary Theresa](https://www.quantisnow.com/insight/sec-form-3-filed-by-coelho-mary-theresa-1680677)
- 2021-08-17 11:00 UTC [AzurRx BioPharma Announces WHO Publication of "Adrulipase Alfa" as International Nonproprietary Name for MS1819](https://www.quantisnow.com/insight/azurrx-biopharma-announces-who-publication-of-adrulipase-alfa-as-international-1676166)
- 2021-08-16 20:48 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by AzurRx BioPharma, Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-azurrx-biopharma-inc-1674591)
- 2021-08-16 20:09 UTC [SEC Form 8-K] [AzurRx BioPharma, Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/azurrx-biopharma-inc-filed-sec-form-8-k-leadership-update-regulation-1674151)
- 2021-08-16 12:00 UTC [Leadership Update] [AzurRx BioPharma Announces Appointment of Terry Coelho to its Board of Directors](https://www.quantisnow.com/insight/azurrx-biopharma-announces-appointment-of-terry-coelho-to-its-board-1670993)
- 2021-08-12 11:00 UTC [AzurRx BioPharma Completes Initial Cohort Enrollment into Part 1 of its RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections](https://www.quantisnow.com/insight/azurrx-biopharma-completes-initial-cohort-enrollment-into-part-1-of-1659934)
- 2021-08-10 11:00 UTC [Public Offering] [AzurRx BioPharma Adds New Clinical Trial Sites in Ukraine for Phase 2 RESERVOIR Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections](https://www.quantisnow.com/insight/azurrx-biopharma-adds-new-clinical-trial-sites-in-ukraine-for-1647393)
- 2021-08-02 10:16 UTC [Analyst Coverage Reiterated] [HC Wainwright & Co. reiterated coverage on AzurRx BioPharma with a new price target](https://www.quantisnow.com/insight/hc-wainwright-co-reiterated-coverage-on-azurrx-biopharma-with-a-1577605)
- 2021-07-27 21:25 UTC [SEC Form 8-K] [AzurRx BioPharma, Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events](https://www.quantisnow.com/insight/azurrx-biopharma-inc-filed-sec-form-8-k-entry-into-a-1520318)
- 2021-07-27 20:30 UTC [Public Offering] [AzurRx BioPharma Announces Closing of $5.75 Million Bought Deal Offering and Exercise in Full of Underwriter's Option to Purchase Additional Shares](https://www.quantisnow.com/insight/azurrx-biopharma-announces-closing-of-575-million-bought-deal-offering-1518176)
- 2021-07-26 21:15 UTC [SEC Form 424B5] [SEC Form 424B5 filed by AzurRx BioPharma, Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-azurrx-biopharma-inc-1500283)
- 2021-07-23 01:54 UTC [SEC Form FWP] [SEC Form FWP filed by AzurRx BioPharma, Inc.](https://www.quantisnow.com/insight/sec-form-fwp-filed-by-azurrx-biopharma-inc-1470735)
- 2021-07-23 01:40 UTC [Public Offering] [AzurRx BioPharma Increases Previously Announced Bought Deal to $5.0 Million](https://www.quantisnow.com/insight/azurrx-biopharma-increases-previously-announced-bought-deal-to-50-million-1468605)
- 2021-07-22 21:06 UTC [SEC Form FWP] [SEC Form FWP filed by AzurRx BioPharma, Inc.](https://www.quantisnow.com/insight/sec-form-fwp-filed-by-azurrx-biopharma-inc-1466626)
- 2021-07-22 21:04 UTC [SEC Form 424B5] [SEC Form 424B5 filed by AzurRx BioPharma, Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-azurrx-biopharma-inc-1466517)
- 2021-07-22 20:51 UTC [Public Offering] [AzurRx BioPharma Announces $3.0 Million Bought Deal Offering of Common Stock](https://www.quantisnow.com/insight/azurrx-biopharma-announces-30-million-bought-deal-offering-of-common-1466022)
- 2021-07-09 21:09 UTC [SEC Form 8-K] [AzurRx BioPharma, Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/azurrx-biopharma-inc-filed-sec-form-8-k-leadership-update-1317591)
- 2021-07-09 21:11 UTC [SEC Form 4] [SEC Form 4 filed by Pennington James](https://www.quantisnow.com/insight/sec-form-4-filed-by-pennington-james-1317576)
- 2021-07-02 21:07 UTC [SEC Form 4] [SEC Form 4 filed by SAPIRSTEIN JAMES](https://www.quantisnow.com/insight/sec-form-4-filed-by-sapirstein-james-1245184)
- 2021-07-02 21:09 UTC [SEC Form 4] [SEC Form 4 filed by Schneiderman Daniel H](https://www.quantisnow.com/insight/sec-form-4-filed-by-schneiderman-daniel-h-1245158)
- 2021-07-02 21:06 UTC [SEC Form 8-K] [AzurRx BioPharma, Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/azurrx-biopharma-inc-filed-sec-form-8-k-leadership-update-1245123)
- 2021-06-17 20:57 UTC [SEC Form 8-K] [AzurRx BioPharma, Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/azurrx-biopharma-inc-filed-sec-form-8-k-notice-of-delisting-1059141)
- 2021-06-08 11:00 UTC [Conference Announcement] [AzurRx BioPharma CEO James Sapirstein to Present at 2021 BIO Digital ](https://www.quantisnow.com/insight/azurrx-biopharma-ceo-james-sapirstein-to-present-at-2021-bio-969739)
- 2021-06-04 18:01 UTC [UPDATE - FMW Media, Inc.’s “New to The Street” TV Announces 6 Interviews Being Broadcast on NEWSMAX TV, Sunday, June 06, 2021, Hour Slot 10-11 AM ET ](https://www.quantisnow.com/insight/update---fmw-media-incs-new-to-the-street-tv-962414)
- 2021-06-04 17:02 UTC [FMW Media, Inc.’s “New to The Street” TV Announces 6 Interviews Being Broadcast on NEWSMAX TV, Sunday, June 06, 2021, Hour Slot 10-11 AM ET ](https://www.quantisnow.com/insight/fmw-media-incs-new-to-the-street-tv-announces-6-962281)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/AZRX
- Earnings history: https://www.quantisnow.com/earnings/AZRX
- Dividend history: https://www.quantisnow.com/dividends/AZRX
- Insider transactions: https://www.quantisnow.com/insiders/AZRX
- Options chain: https://www.quantisnow.com/options/AZRX
- SEC 8-K filings only: https://www.quantisnow.com/company/AZRX/8-k
- RSS and alerts for AZRX: https://www.quantisnow.com/docs/rss-feeds.md
